# Remestemcel PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/remestemcel

> The FDA approved remestemcel, sponsored by MESOBLAST LTD (MESO), on December 18, 2024 for children 2 months and older with SR-aGVHD.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is remestemcel FDA approved?

Yes. The FDA approved remestemcel, sponsored by MESOBLAST LTD (MESO), on December 18, 2024 for children 2 months and older with SR-aGVHD. Press release filed with the SEC (EX-99): "Melbourne, Australia; December 19 and New York, USA; December 18, 2024: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the Food and Drug Administration (FDA) approved Ryoncil® (remestemcel-L) as the first mesenchymal stromal cell (MSC) therapy in the United States." [Calendar and source filings](https://sec-api.dev/pdufa/remestemcel)

Source: Press release filed with the SEC (EX-99), accession 0001345099-24-000087, https://www.sec.gov/Archives/edgar/data/1345099/000134509924000087/exhibit991.htm (retrieved 2026-11-12). Last confirmed 2026-10-13. Cite: https://sec-api.dev/pdufa/remestemcel#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | remestemcel |
| Codes |  |
| Sponsor | MESOBLAST LTD (MESO) https://sec-api.dev/companies/meso/catalysts |
| Indications | children 2 months and older with sr-agvhd, sr- agvhd in pediatric patients 2 months and older, [children with sr-agvhd](https://sec-api.dev/indications/children-with-sr-agvhd), children with steroid-refractory acute graft |
| Modality | cell_therapy |
| FDA designations | orphan |

## Timeline

### August 1, 2023: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "COMPLETE RESPONSE letter dated 08/01/2023 for BL 125706 to Mesoblast, Inc.." https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA125706_20230801.pdf%22

### Jul 2024: NDA/BLA submission

- Status: completed. Date confidence: month. Indication: children with SR-aGVHD.
- First seen 2025-08-29, last confirmed 2025-10-28.
- Press release filed with the SEC (EX-99) (accession 0001345099-25-000090): "In July 2024 we resubmitted the BLA for approval of remestemcel-L in the treatment of children with SR-aGVHD" https://www.sec.gov/Archives/edgar/data/1345099/000134509925000090/exhibit991annualreportno.htm
- SEC Form 10-K (accession 0001345099-25-000067): "•In July 2024 we resubmitted the BLA for approval of remestemcel-L in the treatment of children with SR-aGVHD" https://www.sec.gov/Archives/edgar/data/1345099/000134509925000067/meso-20250630.htm

### Jul 2024: NDA/BLA acceptance

- Status: completed. Date confidence: month. Indication: children with steroid-refractory acute graft.
- First seen 2025-10-28, last confirmed 2025-10-28.
- Press release filed with the SEC (EX-99) (accession 0001345099-25-000090): "July 2024 Announced the FDA accepted our Biologics License Application ("BLA") resubmission for Ryoncil® (remestemcel-L) in the treatment of children with steroid-refractory acute graft versus host disease ("SR-aGVHD")." https://www.sec.gov/Archives/edgar/data/1345099/000134509925000090/exhibit991annualreportno.htm

### December 18, 2024: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: children 2 months and older with SR-aGVHD.
- First seen 2024-12-20, last confirmed 2026-10-13.
- Press release filed with the SEC (EX-99) (accession 0001345099-24-000087): "Melbourne, Australia; December 19 and New York, USA; December 18, 2024: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the Food and Drug Administration (FDA) approved Ryoncil® (remestemcel-L) as the first mesenchymal stromal cell (MSC) therapy in the United States." https://www.sec.gov/Archives/edgar/data/1345099/000134509924000087/exhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0001345099-26-000087): "Access to Healthcare In December 2024, FDA approved Ryoncil® (remestemcel-L-rknd) in the treatment of children 2 months and older with SR-aGVHD." https://www.sec.gov/Archives/edgar/data/1345099/000134509926000087/exhibit991annualreportag.htm
- Press release filed with the SEC (EX-99) (accession 0001345099-26-000087): "Mesoblast received FDA approval in December 2024 for Ryoncil® (remestemcel-L-rknd) for the treatment of SR- aGvHD in pediatric patients 2 months and older, including adolescents and teenagers." https://www.sec.gov/Archives/edgar/data/1345099/000134509926000087/exhibit991annualreportag.htm
- Press release filed with the SEC (EX-99) (accession 0001345099-25-000090): "FDA Approval of Ryoncil®: In December 2024, Mesoblast achieved a historic milestone: Ryoncil® (remestemcel-L-rknd) became the first mesenchymal stromal cell (MSC) therapy to gain FDA approval in the U.S. for any indication." https://www.sec.gov/Archives/edgar/data/1345099/000134509925000090/exhibit991annualreportno.htm
- Press release filed with the SEC (EX-99) (accession 0001345099-25-000090): "Access to Healthcare In December 2024, FDA approved Ryoncil® (remestemcel-L-rknd) in the treatment of children 2 months and older with SR-aGVHD." https://www.sec.gov/Archives/edgar/data/1345099/000134509925000090/exhibit991annualreportno.htm
- Press release filed with the SEC (EX-99) (accession 0001345099-25-000090): "Mesoblast received FDA approval in December 2024 for Ryoncil® (remestemcel-L-rknd) for the treatment of SR- aGvHD in pediatric patients 2 months and older, including adolescents and teenagers." https://www.sec.gov/Archives/edgar/data/1345099/000134509925000090/exhibit991annualreportno.htm

### 2H 2027: topline data readout

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2026-11-12, last confirmed 2026-11-12.
- Press release filed with the SEC (EX-99) (accession 0001345099-26-000097): "A successful outcome of the CLBP Phase 3 trial readout during the second half of calendar 2027 will underpin one of the most valuable commercial opportunities in our portfolio." https://www.sec.gov/Archives/edgar/data/1345099/000134509926000097/exhibit9942026agmappendi.htm

## Same indication

- [Ryoncil (ryoncil)](https://sec-api.dev/pdufa/ryoncil) (MESO)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/remestemcel.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Remestemcel PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/remestemcel

```bibtex
@misc{secapidev_pdufa_remestemcel_20261116,
  title        = {Remestemcel PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/remestemcel}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_remestemcel_20261116","title":"Remestemcel PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/remestemcel","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
